Cingulate CING 深 沪
等待开盘 08-24 09:30:00 美东时间
5.55
+0.220
+4.13%
华盛通- 最 高5.55
- 今 开5.35
- 成交量 23.47万股
- 最 低 5.18
- 昨 收 5.33
- 总市值 8070.71万
- 52周最高 11.89
- 市盈率 静 --
- 换手率 1.61%
- 52周最低 3.16
- 委 比 3.52%
- 总股本 1454.18万
- 历史最高 1236.00
- 量 比 1.67
- 振 幅 6.94%
- 历史最低 2.574
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $52 to $44.
08-20 17:54
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14) per share from the same period last year.
08-13 20:57
Cingulate Restructures Leadership, Eliminates Chief Legal Officer
Cingulate Inc ( ($CING) ) has provided an update. On July 17, 2026, Cingulate I...
07-24 04:36
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy
The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. Cingulate expects a prompt
06-02 20:05
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy and maintains $20 price target.
05-26 18:45
Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.53) by 79.25 percent. This is a 10.38 percent increase over losses of $(1.06) per share from the
05-14 20:44
美股夜盘 | Akanda Corp涨22.72%，QuantumScape涨20.25%
Akanda Corp涨22.72%；QuantumScape涨20.25%；联合租赁涨14.35%
04-23 09:01
